Clinical Trial Update: Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer [Phase 1]

View source ↗

Summary

A Phase 1 study evaluated intravenous interleukin-4 PE38KDEL cytotoxin in patients with recurrent or metastatic breast cancer, renal cell carcinoma, or non-smal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma

Drugs mentioned

• Interleukin-4 PE38KDEL cytotoxin (interleukin-4-PE38KDEL cytotoxin)

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Breast Cancer, Kidney Cancer | Phase 1 | Status: COMPLETED